Navigation Links
NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
Date:9/6/2011

LOS ANGELES, Sept. 6, 2011 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based medical device company, today announced it has received a notice of award for an NIH Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disorders and Stroke (NINDS).  This will support further development of external trigeminal nerve stimulation (eTNS™) therapy for the treatment of drug-resistant epilepsy, for which NeuroSigma is the exclusive worldwide licensee of intellectual property developed by the University of California, Los Angeles (UCLA).  The STTR program requires that the small business collaborates with a non-profit research institution, which must perform at least 30% of the work.  UCLA's role as a subcontractor in this project is primarily focused on conducting the human clinical studies.

NeuroSigma's grant award from NINDS extends over a period of approximately two years and will provide total funding of approximately $750,000, with the second year of funding subject to the availability of funds and satisfactory progress during the first year.  The NINDS STTR program may provide up to an additional $3 million of follow-on Phase II funding for additional clinical studies.  The major focus of the project is clinical testing of a new proprietary eTNS™ pulse generator and animal and human testing of a new generation of electrodes designed to mitigate minor skin irritation, which was the primary side-effect reported by subjects in the Phase I and recently completed Phase II clinical trials.

NeuroSigma's eTNS™ system utilizes a self-adhesive conductive pad applied to the forehead to stimulate branches of the trigeminal nerve, which are located very close to the surface of the skin of the forehead.  The trigeminal nerve is the largest cranial nerve, offering a high-bandwidth pathway for signals to enter the brain.  

Drs. Christopher DeGiorgio and Ian Cook, UCLA faculty in the Departments of Neurology and Psychiatry, are the principal investigators of this project.  Together they have pioneered TNS for epilepsy, depression, post-traumatic stress disorder and other indications.

"We have already seen the safety and efficacy of our non-invasive eTNS™ therapy in prior clinical trials and look forward to the opportunity to further validate our therapy through the valuable funding provided by NINDS," said Dr. DeGiorgio.  "We are also very pleased to receive this grant knowing that NIH's highly regarded peer review process includes a rigorous review by leading medical experts."

CAUTION: The eTNS™ system is an investigational device and at this time is limited by United States law for investigational use only.

About NeuroSigma, Inc.

NeuroSigma is a Los Angeles-based medical technology company established to develop early stage technologies with the potential to transform medical practice. Currently, NeuroSigma is focused on a number of neuromodulation therapies and through our majority-owned subsidiary, NSVascular, on Thin-Film Nitinol covered stents for endovascular applications. NeuroSigma employs two neuromodulation therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed significant intellectual property that is based on technology licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS. For more information about NeuroSigma, please visit our website at http://www.neurosigma.com.


'/>"/>
SOURCE NeuroSigma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
2. NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLAs Thin-Film Nitinol (TFN) Stent Technology for Endovascular Applications
3. NeuroSigma, Inc. Retains CCG Investor Relations
4. Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or Off-The-Shelf Stem Cell Treatment for Heart Attacks
5. Lupin Receives Final Approval to Market Generic Ultram® ER
6. Assured Pharmacy, Inc. Receives Gross Proceeds of $400,000 from Sale of Convertible Debentures and Warrants
7. Masimo Pronto-7™ Receives Japanese and Canadian Regulatory Clearances
8. Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
9. Simceres Iremod Receives SFDA New Drug Approval
10. PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
11. WuXi AppTec Bioanalytical Services Unit Receives GLP Certificate from OECD and EU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016  Redwood Scientific Technologies, Inc. announced today ... to help women balance their hormones. This product will ... Jason Cardiff , President and CEO. "I ... help the millions of women across the country and ... imbalanced hormones. Our research and development team is confident ...
(Date:2/5/2016)... in Alabama seeking prostate care with ... have to travel out of state. Vituro Health ... of Alabama to provide a total prostate management program ... Alabama is known throughout the ... using many different modalities. They are the largest and one ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
Breaking Medicine Technology:
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... ... announced the availability of the company's lighter, sleeker next generation LYNX VR Indoor ... plant. , Improvements in design and manufacturing not only reduce the weight ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... , ... Boar’s Head Brand®, one of the nation’s leading providers of premium ... the stress out of your party preparation – follow these easy, yet delicious recipes ... the game. , “The key to hosting a successful game-day party is creating a ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Ben Amini, a ... now welcoming orthodontist, Dr. Amanda Cheng, to the practice. With the addition of ... care, including general dentistry, cosmetic treatments, periodontics, implant dentistry , endodontics, orthodontics ...
Breaking Medicine News(10 mins):